Program
Telmisartan
Also written as “telmisartan”, “CKD-828, D097, D337” and “Telmisartan 40 mg”.
Its studies are mostly in Hypertension · Essential Hypertension · Diabetic Nephropathies · Hypercholesterolemia · Hyperlipidemias, led by 15 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 900 open or running | phase 4since May 2, 2002 | May 2, 2002 | none ahead |
| Chong Kun Dang Pharmaceutical | 122 open or running | phase 4since Mar 9, 2023 | May 20, 2010 | none ahead |
| Yuhan | 81 open or running | phase 4since Nov 10, 2016 | May 29, 2014 | none ahead |
| IlDong Pharmaceutical | 40 open or running | phase 3since Mar 5, 2014 | Mar 5, 2014 | none ahead |
| Jeil Pharmaceutical | 30 open or running | phase 3since Mar 8, 2017 | Mar 9, 2015 | none ahead |
| Daewon Pharmaceutical | 20 open or running | phase 3since Oct 12, 2016 | Oct 12, 2016 | none ahead |
| George Medicines PTY | 20 open or running | phase 3since Aug 15, 2020 | Aug 15, 2020 | none ahead |
| HK inno.N | 20 open or running | phase 1since Aug 25, 2021 | Aug 25, 2021 | none ahead |
| Daewoong Pharmaceutical | 10 open or running | phase 1since Mar 4, 2013 | Mar 4, 2013 | none ahead |
| dongkoo-bio-pharma | 10 open or running | phase 1since Feb 8, 2018 | Feb 8, 2018 | none ahead |
| Hanlim Pharm. | 10 open or running | phase 3since Dec 2, 2020 | Dec 2, 2020 | none ahead |
| Huons Global | 11 open or running | phase 1since Aug 5, 2026 | Aug 5, 2026 | Apr 2027phase 1 · NCT07784608 |
| Pharmtechnology | 10 open or running | phase 1since Oct 8, 2018 | Oct 8, 2018 | none ahead |
| samil-pharmaceutical-co-ltd | 10 open or running | phase 1since Oct 13, 2015 | Oct 13, 2015 | none ahead |
| thpharm-corp | 10 open or running | phase 1since Sep 8, 2023 | Sep 8, 2023 | none ahead |
Also a collaborator on its studies: linical-korea, GlaxoSmithKline and Bayer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Aug 12, 2014.
- Aug 15, 2020George Medicines PTY's first studies: 2 phase 3 studies in HypertensionNew to George Medicines PTYGeorge Medicines PTY · NCT04518306, NCT04518293
- Dec 2, 2020Hanlim Pharm.'s first study: phase 3 study in HypertensionNew to Hanlim Pharm.Hanlim Pharm. · NCT04659070 · 156 enrolled · Korea, Republic of
- Apr 29, 2021Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT04883658 · 62 enrolled · Korea, Republic of
- Aug 25, 2021HK inno.N's first study: phase 1 study in HypertensionNew to HK inno.NHK inno.N · NCT05040880 · 46 enrolled · Korea, Republic of
- Jan 4, 2022Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT05192356 · 63 enrolled · Korea, Republic of
- Jan 23, 2022Phase 1 study in HypertensionHK inno.N · NCT05223101 · 46 enrolled · Korea, Republic of
- Sep 18, 2022Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT05549401 · 32 enrolled · Korea, Republic of
- Feb 20, 2023Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT05749861 · 65 enrolled · Korea, Republic of
- Mar 9, 2023Phase 4 study in Essential HypertensionChong Kun Dang Pharmaceutical · NCT05843162 · 116 planned
- Sep 4, 2023Phase 4 study in Essential HypertensionYuhan · NCT06041529 · 198 enrolled · South Korea
- Sep 8, 2023thpharm-corp's first study: phase 1 study in HypertensionNew to thpharm-corpthpharm-corp · NCT06063109 · 51 enrolled · South Korea
- Oct 29, 2023Phase 1 study in HypertensionChong Kun Dang Pharmaceutical · NCT06112678 · 63 enrolled · Korea, Republic of
- May 22, 2024Phase 4 study in Diabetic NephropathiesChong Kun Dang Pharmaceutical · NCT06431477 · 98 planned · Korea, Republic of
- Aug 5, 2026Huons Global's first study: phase 1 study in Drug-drug InteractionsNew to Huons GlobalHuons Global · NCT07784608 · 28 planned · South Korea
Ahead
- Apr 2027Primary completion: phase 1 study in Drug-drug InteractionsHuons Global · NCT07784608
TargetBeta
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Other programs on AGTR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Valsartanrule | Novartis | phase 4 | 145 |
| Losartanrule | Organon | phase 4 | 58 |
| azilsartan medoxomilrule | Takeda | phase 4 | 25 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
Studies
The newest 60 of 130 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07784608Drug-drug Interactions · South Korea | 1 | Not yet recruiting | Huons Global | Apr 2027 | 28 |
| NCT06431477Diabetic Nephropathies · Korea, Republic of | 4 | Recruiting | Chong Kun Dang Pharmaceutical | Oct 31, 2025 | 98 |
| NCT06112678Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Feb 19, 2024 | 63 |
| NCT06063109Hypertension · South Korea | 1 | Completed | thpharm-corp | Nov 9, 2023 | 51 |
| NCT06041529Essential Hypertension · South Korea | 4 | Active, not recruiting | Yuhan | Feb 28, 2026 | 198 |
| NCT05843162Essential Hypertension | 4 | Not yet recruiting | Chong Kun Dang Pharmaceutical | Dec 31, 2023 | 116 |
| NCT05749861Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jun 7, 2023 | 65 |
| NCT05549401Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Nov 30, 2022 | 32 |
| NCT05223101Hypertension · Korea, Republic of | 1 | UNKNOWN | HK inno.N | Jul 2022 | 46 |
| NCT05192356Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | May 8, 2022 | 63 |
| NCT05040880Hypertension · Korea, Republic of | 1 | Completed | HK inno.N | Oct 31, 2021 | 46 |
| NCT04883658Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jul 20, 2021 | 62 |
| NCT04659070Hypertension · Korea, Republic of | 3 | UNKNOWN | Hanlim Pharm. | May 19, 2022 | 156 |
| NCT04518306Hypertension · United States, Australia, Nigeria and more | 3 | Completed | George Medicines PTY | Sep 19, 2023 | 755 |
| NCT04518293Hypertension · United States, Australia, Czechia and more | 3 | Completed | George Medicines PTY | Aug 11, 2023 | 1,385 |
| NCT04258865Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Apr 26, 2020 | 30 |
| NCT04158076Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Jan 14, 2021 | 131 |
| NCT03889145Healthy | 1 | Completed | IlDong Pharmaceutical | Feb 19, 2014 | 30 |
| NCT03872232Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Aug 12, 2020 | 180 |
| NCT03705533Bioequivalence · Canada | 1 | Completed | Pharmtechnology | Dec 16, 2018 | 26 |
| NCT03662620Hypertension · Korea, Republic of | 1 | Completed | Yuhan | Dec 8, 2018 | 67 |
| NCT03566316Hypertension With Hyperlipidemia · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Jun 16, 2017 | 134 |
| NCT03550859Renal Insufficiency, Chronic · Korea, Republic of | 4 | UNKNOWN | Yuhan | Dec 2021 | 374 |
| NCT03461081Hypertension With Hyperlipidemia · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Jul 12, 2017 | 32 |
| NCT03438955Hyperlipidemias · Korea, Republic of | 1 | UNKNOWN | dongkoo-bio-pharma | Jul 31, 2018 | 48 |
| NCT03088254Dyslipidemia With Hypertension · Korea, Republic of | 3 | Completed | Jeil Pharmaceutical | Jul 31, 2017 | 126 |
| NCT02968160Metabolic Syndrome · Korea, Republic of | 4 | Terminated | Yuhan | Feb 2018 | 55 |
| NCT03210532Hypertension · Korea, Republic of | 3 | Completed | Daewon Pharmaceutical | Sep 2017 | 129 |
| NCT02933658Hypertension | 1 | Completed | Daewon Pharmaceutical | Nov 2015 | 71 |
| NCT02738632Essential Hypertension · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Aug 2016 | 300 |
| NCT02579356Essential Hypertension · Korea, Republic of | 1 | Completed | samil-pharmaceutical-co-ltd | Aug 2014 | 48 |
| NCT02387619Hypertension · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Mar 2015 | 41 |
| NCT02276391Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2008 | 64 |
| NCT02269176Hypertension | 3 | Completed | Boehringer Ingelheim | Jan 2001 | 330 |
| NCT02263989Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2007 | 30 |
| NCT02262858Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2005 | 68 |
| NCT02262793Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2004 | 24 |
| NCT02262780Healthy | 1 | Completed | Boehringer Ingelheim | Feb 15, 2004 | 20 |
| NCT02262650Healthy | 1 | Completed | Boehringer Ingelheim | May 2004 | 24 |
| NCT02262624Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2005 | 36 |
| NCT02262598Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2004 | 30 |
| NCT02262585Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2002 | 30 |
| NCT02262572Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2003 | 24 |
| NCT02262559Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2002 | 30 |
| NCT02261129Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2008 | 64 |
| NCT02261116Healthy | 4 | Completed | Boehringer Ingelheim | Aug 2002 | 24 |
| NCT02261064Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2009 | 32 |
| NCT02260089Hypertension | 4 | Completed | Boehringer Ingelheim | Jul 2002 | 134 |
| NCT02259829Healthy | 1 | Completed | Boehringer Ingelheim | Nov 2007 | 84 |
| NCT02259816Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2006 | 38 |
| NCT02259803Healthy | 1 | Completed | Boehringer Ingelheim | Nov 2007 | 30 |
| NCT02259790Healthy | 1 | Completed | Boehringer Ingelheim | Aug 2007 | 30 |
| NCT02242812Hypertension | 4 | Terminated | Boehringer Ingelheim | Oct 2004 | 24 |
| NCT02242370Hypertension | 4 | Completed | Boehringer Ingelheim | Nov 2000 | 3,045 |
| NCT02242344Hypertension | 2 | Completed | Boehringer Ingelheim | Sep 2007 | 77 |
| NCT02242318Hypertension | 4 | Completed | Boehringer Ingelheim | Sep 2002 | 440 |
| NCT02233218Healthy Male Volunteer · Korea, Republic of | 1 | Completed | Yuhan | Oct 2014 | 60 |
| NCT02218684Healthy | 1 | Completed | Boehringer Ingelheim | Nov 1998 | 27 |
| NCT02215005Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2007 | 42 |
| NCT02214992Healthy | 1 | Completed | Boehringer Ingelheim | Jun 2007 | 84 |
How it is read
Names in the registry
- “Telmisartan”, 38 entries
- “telmisartan”, 7 entries
- “CKD-828, D097, D337”, 6 entries
- “Telmisartan 40 mg”, 6 entries
- “Low dose of telmisartan”, 4 entries
Conditions, from the studies’ own filings
- Hypertension, 77 studies
- Essential Hypertension, 6 studies
- Diabetic Nephropathies, 3 studies
- Hypercholesterolemia, 2 studies
- Hyperlipidemias, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.